SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/ex1-1.htm

Chunk 12 of 21
Word Count: 1460
Character Count: 9573

Document Content:

defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.

Testing-the-Waters Communications. If at any time following the distribution of any Written Testing-the-Waters Communication there
occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein,
in light of the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative
and shall promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such
untrue statement or omission.

Delivery to the Underwriters of Registration Statements. The Company has delivered or made available or shall deliver or make
available to the Representative and counsel for the Representative, upon request and without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates
of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed
and each amendment thereto (without exhibits) for each of the Underwriters, upon receipt of a written request therefor. The copies of
the Registration Statement and each amendment thereto furnished to the Underwriters will be identical to the electronically transmitted
copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

Delivery to the Underwriters of Prospectuses. The Company has delivered or made available or will deliver or make available to
each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested, and the Company
hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each Underwriter,
without charge, during the period when a prospectus relating to the Public Shares, the Representative’s Warrants and/or the Representative
Warrant Shares is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, such
number of copies of the Prospectus (as amended or supplemented) as such Underwriter may reasonably request. The Prospectus and any amendments
or supplements thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the
Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T.

[Reserved].

Review of Financial Statements. For a period of two (2) years after the date of this Agreement, the Company, at its expense, shall
use its commercially reasonable efforts to cause its regularly engaged independent registered public accounting firm to review (but not
audit) the Company’s interim financial statements immediately preceding the announcement of any interim financial information.

Listing. The Company shall use its commercially reasonable efforts to list for trading, subject only to official notice of issuance,
the Public Shares and the Representative Warrant Shares on the Exchange and to maintain the listing of the Common Stock on the Exchange
for at least two (2) years from the date of this Agreement.

Reports to the Representative.

Periodic Reports, etc. For a period of two (2) years after the date of this Agreement, the Company shall furnish or make available
to the Representative copies of such financial statements and other periodic and special reports as the Company from time to time furnishes
generally to holders of any class of its securities and also promptly furnish to the Representative: (i) a copy of each periodic report
the Company shall be required to file with the Commission under the Exchange Act and the Exchange Act Regulations; (ii) a copy of every
press release and every news item and article with respect to the Company or its affairs which was released by the Company; (iii) a copy
of each Form 8-K prepared and filed or furnished by the Company; and (iv) a copy of each registration statement filed by the Company
under the Securities Act; provided the Representative shall sign, if requested by the Company, a Regulation FD compliant confidentiality
agreement which is reasonably acceptable to the Representative and Representative Counsel in connection with the Representative’s
receipt of such information. Documents filed with the Commission pursuant to its EDGAR system (or with respect to articles and press
releases, posted on the Company’s website) shall be deemed to have been delivered to the Representative pursuant to this Section

Transfer Agent; Transfer Sheets. For a period of one (1) year after the date of this Agreement, the Company shall retain a transfer
agent and registrar acceptable to the Representative (the “Transfer Agent”) and shall furnish to the Representative
at the Company’s sole cost and expense such transfer sheets of the Company’s securities as the Representative may reasonably
request, including the daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Equniti Trust Company, LLC is acceptable
to the Representative to act as Transfer Agent for the Common Stock.

Payment of Expenses.

General Expenses Related to the Offering. The Company hereby agrees to pay on the Closing Date and on any Option Closing Date
to the extent not paid on the Closing Date, all expenses incident to the performance of the obligations of the Company under this Agreement,
including, but not limited to: (a) all filing fees and communication expenses relating to the registration of the Public Shares, the
Representative’s Warrants and the Representative Warrant Shares with the Commission; (b) all public filing system filing fees associated
with the review of the Offering by FINRA; (c) all fees and expenses relating to the listing of the Public Shares and the Representative
Warrant Shares on the Exchange and such other stock exchanges as the Company and the Representative together determine; (d) all fees,
expenses and disbursements relating to the registration or qualification of the Public Shares, the Representative’s Warrants and
the Representative Warrant Shares under the “blue sky” securities laws of such states and other jurisdictions as the Representative
may reasonably designate (including, without limitation, all filing and registration fees); (e) all fees, expenses and disbursements
relating to the registration, qualification or exemption of the Public Shares, the Representative’s Warrants and the Representative
Warrant Shares under the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f) the costs
of all mailing and printing of the Registration Statements, Prospectuses and all amendments, supplements and exhibits thereto and as
many preliminary and final Prospectuses as the Representative may reasonably deem necessary; (g) the costs and expenses of the Company’s
investor relations firm; (h) fees and expenses of the Transfer Agent; (i) the fees and expenses of the Company’s accountants; (j)
the fees and expenses of the Company’s legal counsel and other agents and representatives; (k) fees and expenses of the Representative’s
legal counsel; (l) the costs associated with the Underwriter’s use of Ipreo’s book-building, prospectus tracking and compliance
software for the Offering; (m) the Underwriters’ actual accountable “road show” expenses; and (n) the costs associated
with receiving commemorative mementos and lucite tombstones. The Underwriters shall be entitled to reimbursement by the Company for all
reasonable and documented expenses under Section 3.9.1 – (n), which reimbursement shall not exceed $150,000. In addition,
the Company shall be responsible for all fees, expenses and disbursements relating to background checks of the Company’s officers
and directors in an amount not to exceed $7,500 in the aggregate. It is acknowledged that the Company has heretofore paid a retainer
to the Representative of an aggregate of $[60,000] (the “Retainer”), which shall be applied against the accountable
expenses under this Section 3.9.1. The Representative may deduct from the net proceeds of the Offering payable to the Company on the
Closing Date and on any Option Closing Date, the expenses set forth herein to be paid by the Company to the Underwriters. Any portion
of the Retainer in excess of expenses actually incurred shall be returned to the Company.